143 related articles for article (PubMed ID: 8636769)
1. No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule.
Younes A; Ayoub JP; Hagemeister FB; McLaughlin P; Sarris A; Rodriguez MA; Swan F; Romaguera JE; Martin J; Cabanillas F
J Clin Oncol; 1996 Feb; 14(2):543-8. PubMed ID: 8636769
[TBL] [Abstract][Full Text] [Related]
2. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma.
Younes A; Sarris A; Melnyk A; Romaguera J; McLaughlin P; Swan F; Rodriguez MA; Hagemeister F; Moore D; North L
J Clin Oncol; 1995 Mar; 13(3):583-7. PubMed ID: 7884419
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
Casasnovas RO; Haioun C; Dumontet C; Gabarre J; Richard B; Lederlin P; Caillot D; Stamatoullas A; Morel P; Quesnel B; Blay JY; Bouabdallah K; Gisselbrecht C
Haematologica; 2000 May; 85(5):502-7. PubMed ID: 10800167
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246.
Press OW; LeBlanc M; O'Rourke TJ; Gagnet S; Chapman RA; Balcerzak SP; Fisher RI
J Clin Oncol; 1998 Feb; 16(2):574-8. PubMed ID: 9469343
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel (Taxol) for the treatment of lymphoma.
Younes A; Ayoub JP; Sarris A; North L; Pate O; McLaughlin P; Rodriguez MA; Romaguera J; Hagemeister F; Bachier C; Preti A; Cabanillas F
Ann Oncol; 1997; 8 Suppl 1():129-31. PubMed ID: 9187446
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.
Schiller JH; Storer B; Tutsch K; Arzoomanian R; Alberti D; Feierabend C; Spriggs D
J Clin Oncol; 1994 Feb; 12(2):241-8. PubMed ID: 7509380
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel administered by a 1-hour infusion: A phase I-II trial comparing two schedules.
Hainsworth JD; Raefsky EL; Greco FA
Cancer J Sci Am; 1995; 1(4):281-7. PubMed ID: 9166489
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel-based treatment of lymphoma.
Younes A
Semin Oncol; 1999 Feb; 26(1 Suppl 2):123-8. PubMed ID: 10190794
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
Hainsworth JD; Greco FA
Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
[TBL] [Abstract][Full Text] [Related]
10. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity.
Rosell R; González-Larriba JL; Alberola V; Molina F; Monzó M; Benito D; Pérez JM; de Anta JM
Semin Oncol; 1995 Dec; 22(6 Suppl 14):12-8. PubMed ID: 8553077
[TBL] [Abstract][Full Text] [Related]
11. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease.
Chang AY; Boros L; Garrow G; Asbury R
Semin Oncol; 1995 Jun; 22(3 Suppl 6):124-7. PubMed ID: 7597429
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel (Taxol): phase I/II trial comparing 1-hour infusion schedules.
Greco FA; Hainsworth JD
Semin Oncol; 1994 Oct; 21(5 Suppl 8):3-8. PubMed ID: 7939760
[TBL] [Abstract][Full Text] [Related]
14. Single-agent paclitaxel for the treatment of breast cancer: an overview.
Hortobagyi GN; Holmes FA
Semin Oncol; 1996 Feb; 23(1 Suppl 1):4-9. PubMed ID: 8629036
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas.
Ajani JA; Ilson DH; Kelsen DP
Semin Oncol; 1996 Oct; 23(5 Suppl 12):55-8. PubMed ID: 8941411
[TBL] [Abstract][Full Text] [Related]
16. Treatment of metastatic breast cancer with paclitaxel and doxorubicin.
Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BW; Ejlertsen B
Semin Oncol; 1995 Dec; 22(6 Suppl 15):13-7. PubMed ID: 8643964
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Younes A; Preti HA; Hagemeister FB; McLaughlin P; Romaguera JE; Rodriguez MA; Samuels BI; Palmer JL; Cabanillas F
Ann Oncol; 2001 Jul; 12(7):923-7. PubMed ID: 11521796
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma.
Sarris AH; Younes A; McLaughlin P; Moore D; Hagemeister F; Swan F; Rodriguez MA; Romaguera J; North L; Mansfield P; Callendar D; Mesina O; Cabanillas F
J Clin Oncol; 1996 Jan; 14(1):233-9. PubMed ID: 8558203
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
20. Single-agent paclitaxel as a 3-hour infusion.
Gatzemeier U; Neuhauss R; Schluter I; von Pawel J; Wagner H; Diergarten K
Semin Oncol; 1996 Dec; 23(6 Suppl 16):94-7. PubMed ID: 9007132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]